These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 27706103)
1. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. Geldof L; Deventer K; Roels K; Tudela E; Van Eeno P Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706103 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease. Roby DA; Ruiz F; Kermath BA; Voorhees JR; Niehoff M; Zhang J; Morley JE; Musiek ES; Farr SA; Burris TP PLoS One; 2019; 14(4):e0215004. PubMed ID: 30973894 [TBL] [Abstract][Full Text] [Related]
3. Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach: Potential applications in doping control. Kwak YB; Yoon J; Yoo HH J Pharm Biomed Anal; 2024 Aug; 246():116190. PubMed ID: 38735208 [TBL] [Abstract][Full Text] [Related]
4. Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-α agonists. Li L; Yang C; Qiao X; Yang X; Zhang J; Cui M; Li Z; Tian A; Li X; Zou X; Li Y; He W; Chen Y; He X Bioorg Med Chem; 2024 Sep; 111():117845. PubMed ID: 39059249 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Sulli G; Rommel A; Wang X; Kolar MJ; Puca F; Saghatelian A; Plikus MV; Verma IM; Panda S Nature; 2018 Jan; 553(7688):351-355. PubMed ID: 29320480 [TBL] [Abstract][Full Text] [Related]
9. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action. Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548 [No Abstract] [Full Text] [Related]
11. REV-ERB and ROR: therapeutic targets for treating myopathies. Welch RD; Flaveny CA Phys Biol; 2017 Jun; 14(4):045002. PubMed ID: 28586319 [TBL] [Abstract][Full Text] [Related]
12. Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism. Stujanna EN; Murakoshi N; Tajiri K; Xu D; Kimura T; Qin R; Feng D; Yonebayashi S; Ogura Y; Yamagami F; Sato A; Nogami A; Aonuma K PLoS One; 2017; 12(12):e0189330. PubMed ID: 29232411 [TBL] [Abstract][Full Text] [Related]
13. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Dierickx P; Emmett MJ; Jiang C; Uehara K; Liu M; Adlanmerini M; Lazar MA Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12147-12152. PubMed ID: 31127047 [TBL] [Abstract][Full Text] [Related]
14. A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009. Mazzarino M; Rizzato N; Stacchini C; de la Torre X; Botrè F Drug Test Anal; 2018 Nov; 10(11-12):1670-1681. PubMed ID: 30395700 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic Effect of SR9009, a REV-ERB Agonist, on the Human Glioblastoma T98G Cells. Wagner PM; Monjes NM; Guido ME ASN Neuro; 2019; 11():1759091419892713. PubMed ID: 31825658 [TBL] [Abstract][Full Text] [Related]
16. REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009. Amador A; Kamenecka TM; Solt LA; Burris TP Biochem Pharmacol; 2018 Apr; 150():1-8. PubMed ID: 29355503 [TBL] [Abstract][Full Text] [Related]
17. The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock. Ishimaru K; Nakajima S; Yu G; Nakamura Y; Nakao A Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847374 [TBL] [Abstract][Full Text] [Related]
19. SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome. Reitz CJ; Alibhai FJ; Khatua TN; Rasouli M; Bridle BW; Burris TP; Martino TA Commun Biol; 2019; 2():353. PubMed ID: 31602405 [TBL] [Abstract][Full Text] [Related]